Bahrain and Kuwait to revoke the ban on Julphar products 

By Rahul Vaimal, Associate Editor
  • Follow author on
Representational Image

Gulf Pharmaceutical Industries (Julphar) will resume its exports to Bahrain and Kuwait again after both countries are expected to revoke their respective bans placed earlier on the firm’s products.

The news comes after the successful review of Julphar’s manufacturing plants by the Gulf Health Council (GHC) and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin from the Ministry of Health, Kuwait.

H.H. Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said, “We are very pleased to announce that, once again, more than 100 products will be registered and available within Bahrain and Kuwait. We would like to extend our thanks to the authorities for their continued guidance and support during our collaboration to implement further improvements in our manufacturing processes as per the recommendations highlighted in their report.

H.H. Sheikh Saqer Humaid Al Qasimi,
Board Chairman, Julphar

“We look forward to being able to serve patients in both countries once again, as well as further bolstering our long-standing relationships and efforts with all relevant Bahraini, Kuwaiti and regional authorities as our products continue to be successfully sold here and in 50 markets around the world.”

Commenting on the lift, Dr. Essam Farouk, Chief Executive Officer at Julphar, said, “Ensuring patients are able to access the products and treatment they need is of the utmost importance to us and this resumption of sales marks the relaunch of our products in all GCC markets. Today is another great stride in the transformation that is underway at Julphar, which has the clear objective to restore our position as a regional pharmaceutical leader within three years.”

In 2019, Julphar began its business transformation involving an internal restructure and a cutting-edge overhaul of all quality processes. This included a principal focus on the company’s quality assurance, regulatory and development activities driven by over 200 scientists, medical professionals and regulatory experts to ensure Julphar provides impactful and accessible healthcare solutions that reciprocate to the requirements of people and governments across the region and beyond.